

## Bilaga 3 Beskrivning av ingående studier

### Innehåll

<i>Studier inom behandling med läkemedel</i> .....	2
<i>Duloxetin jämfört med placebo</i> .....	2
<i>Pregabalin jämfört med placebo</i> .....	4
<i>Studier inom psykologisk behandling</i> .....	6
<i>KBT jämfört med väntelista eller sedvanlig vård</i> .....	6
<i>KBT jämfört med annan intervention</i> .....	11
<i>ACT jämfört med väntelista eller sedvanlig vård</i> .....	12
<i>MBSR jämfört med väntelista eller sedvanlig vård</i> .....	14
<i>MBSR jämfört med annan intervention</i> .....	17
<i>Psykoedukativa insatser jämfört med väntelista eller sedvanlig vård</i> .....	18
<i>Studier inom fysisk aktivitet och manuella behandlingar</i> .....	20
<i>Guidad fysisk aktivitet jämfört med väntelista, sedvanlig behandling eller annan minimal intervention</i> .....	20
<i>Fysioterapeutisk behandling – Guidad fysisk aktivitet jämfört med annan intervention</i> .....	25
<i>Akupunktur</i> .....	30
<i>Behandlingar som undersökts i enbart en studie</i> .....	32
<i>Studier inom behandling med läkemedel</i> .....	32
<i>Studier inom psykologisk behandling</i> .....	34
<i>Studier inom psykoedukativa interventioner</i> .....	36
<i>Studier inom fysisk aktivitet och manuella behandlingar</i> .....	38
<i>Annan behandling</i> .....	40
<i>Referenser</i> .....	41

## Studier inom behandling med läkemedel

### Duloxetin jämfört med placebo

#### Arnold 2010

Author Year Country Ref #	Arnold 2010 USA, Puerto Rico [1]
Study design Setting Recruitment	Randomized controlled trial 48 research centers in the United States and Puerto Rico
Population	Adults w fibromyalgia according to ACR-90 and $\geq 4$ on item "average pain" in BPI.
Inclusion criteria	Patients were included if they were judged to be reliable and had a level of understanding that allowed them to communicate intelligibly and provide informed consent.
Follow up	12 (placebo-controlled phase) and 24 weeks (open-label active treatment phase).
Intervention 1  Participants (n) Drop-outs (n)	Duloxetine 60 -120 mg 1 week titration to steady dose (60 mg/day). Dose escalation week 4 and 8 if <50% pain reduction on BPI (up to 120 mg/day). Dose reduction to tolerance level if needed. 263 Completed intervention: 176/263 Participants included in analysis: 249/263
Comparison Participants (n) Drop-outs (n)	Placebo 267 Completed intervention: 187/267 Participants included in analysis: 258/267
Outcomes	SF-36 Subscales: 1) Mental components 2) Physical components, Brief Pain Inventory (BPI) 1) Severity 2) Interference, Beck Depression Inventory-II (BDI-11), Beck Anxiety Inventory (BAI), Multidimensional Fatigue Inventory (MFI) 1) Total score och 2) 4 subscales, Cognitive and Physical Functioning Questionnaire (CPFQ), Patient Global Assessment (PGI-I), Clinician Global Assessment (CGI-I)
Comments	

#### Arnold 2012

Author Year Country Ref #	Arnold 2012 United States, Mexico, Israel, and Argentina. [2]
Study design Setting Recruitment	Randomized controlled trial 29 outpatient research centers.
Population	Women and men $\geq 18$ years of age with FM (ACR-90) and had a score $\geq 4$ on the average pain severity item of the Brief Pain Inventory (BPI)-Modified Short Form.
Inclusion criteria	
Follow up	12 weeks (end of treatment period).
Intervention 1	Duloxetine Duloxetine 30 mg/d (2 capsules: 1 placebo, 1 duloxetine 30 mg), taken orally.

<b>Participants (n)</b>	155
<b>Drop-outs (n)</b>	Completed post-treatment: 121/155
<b>Comparison</b>	Placebo Placebo (2 capsules: both placebo) taken orally.
<b>Participants (n)</b>	153
<b>Drop-outs (n)</b>	Completed post-treatment: 110/153
<b>Outcomes</b>	FIQ - total score, SF-36 Subscales: 1) Mental components 2) Physical components, Brief Pain Inventory (BPI) Subscales: 1) Severity 2) Interference, Beck Depression Inventory (BDI), Beck Depression Inventory (BDI), Patient Global Assessment (PGI-I)
<b>Comments</b>	Of the 308 patients randomized, 306 (153 in each treatment group) were included in the primary efficacy analysis; 2 patients in the duloxetine 30 mg/d treatment group were lost to follow-up before the postbaseline BPI average pain severity was collected.

### Murakami 2015

<b>Author</b>	Murakami
<b>Year</b>	2015
<b>Country</b>	Japan
<b>Ref #</b>	[3]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	42 outpatient clinics and hospitals in Japan
<b>Recruitment</b>	
<b>Population</b>	Fibromyalgia (ACR-1990), age 20-75 years, BPI average pain score of at least 4 at first 2 visits.
<b>Inclusion criteria</b>	
<b>Follow up</b>	14 weeks (1 week of titration, 12 weeks treatment at target dose and 1 weeks taper phase).
<b>Intervention 1</b>	Duloxetine 60 mg Administered orally, once per day. 60 mg. Escalation phase 20 mg/d for 1 week, 40 mg for 1 week.
<b>Participants (n)</b>	196
<b>Drop-outs (n)</b>	Completed intervention: 166/196 Participants included in analysis: 191/196
<b>Comparison</b>	Placebo Administered orally, once per day.
<b>Participants (n)</b>	197
<b>Drop-outs (n)</b>	Completed intervention: 149/197 Participants included in analysis: 195/197
<b>Outcomes</b>	FIQ - total score och subscales, SF-36 8 subscales, Brief Pain Inventory (BPI) 1) Severity 2) Interference and 7 subscales, Beck Depression Inventory-II (BDI-11), Patient Global Assessment (PGI-I), Clinician Global Assessment (CGI-I)
<b>Comments</b>	

## Pregabalin jämfört med placebo

### Arnold 2008

Author	Arnold
Year	2008
Country	USA
Ref #	[4]
Study design	Randomized controlled trial
Setting	84 research centers
Recruitment	Patients were identified by physician referral or advertisement for a fibromyalgia medication trial.
Population	Patients were aged $\geq 18$ years and had met the 1990 ACR criteria for FM. Male or female (were non pregnant and nonlactating).
Inclusion criteria	Had a pain score of at least 40 mm on the 100-mm pain visual analog scale (VAS) at screening (visit 1) and random assignment (visit 2).
Follow up	Approximately 1 week after completion of the 14-week treatment phase.
Intervention 1	Pregabalin 600 mg/d Two equal doses given orally, 600 mg/day for 12 weeks
Participants (n)	188
Drop-outs (n)	Completed study: 133/188
Intervention 2	Pregabalin 450 mg/d Two equal doses given orally, 450 mg/day for 12 weeks
Participants (n)	190
Drop-outs (n)	Completed study: 125/190
Intervention 2	Pregabalin 300 mg/d Two equal doses given orally, 300 mg/day for 12 weeks
Participants (n)	183
Drop-outs (n)	Completed study: 123/183
Comparison	Placebo Twice daily for 12 weeks
Participants (n)	184
Drop-outs (n)	Completed study: 125/184
Outcomes	FIQ - total score, SF-36 Subscales: 1) Mental components 2) Physical components 3) 8 subscales, NRS – intensity, Hospital Anxiety and Depression Score (HADS), MOS - Sleep Scale, Multidimensional Assessment of Fatigue (MAF), NRS - diary (quality of sleep), Patient global assessment (PGI) PGI-improvement
Comments	Of the 750 randomly assigned subjects, 745 took at least 1 dose of study medication and comprised the ITT population. Five randomly assigned subjects withdrew before initiation of study.

### Ohta 2012

Author	Ohta
Year	2012
Country	Japan
Ref #	[5]
Study design	Randomized controlled trial
Setting	Multicenter study performed in 44 sites in Japan.
Recruitment	
Population	Patients were aged $\geq 18$ years and had met the 1990 ACR criteria for FM.

<b>Inclusion criteria</b>	Patients also had a score of $\geq 40$ mm on the 100 mm pain visual analogue scale (VAS) at Visit 2, and had assessed and documented their pain score on at least four of the past seven days prior to Visit 2 while recording an average pain score of $\geq 4$ on the 11-point numeric rating scale.
<b>Follow up</b>	15 weeks from baseline (after 12 wks fixed dose treatment phase).
<b>Intervention 1</b>	Pregabalin 300 – 450 mg/d Maintenance dose set to either 300 or 450 mg/day at visit 5. 2 times daily (morning & evening).
<b>Participants (n)</b> <b>Drop-outs (n)</b>	251 Received treatment: 250/251 Completed post-treatment: 207/251
<b>Comparison</b>	Placebo 2 times daily (morning & evening).
<b>Participants (n)</b> <b>Drop-outs (n)</b>	250 Received treatment: 248/250 Completed post-treatment: 208/250
<b>Outcomes</b>	FIQ - total score and subscales, SF-36, VAS – intensity, MOS - Sleep Scale,
<b>Comments</b>	

**Pauer 2011**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Pauer 2011 Global study performed in all parts of the world except Africa [6]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial 73 a study centers across Europe, North and South America, Australia, Asia.
<b>Population</b>	Adults (18 years or over) w fibromyalgia according to ACR-90 and w at least moderate pain ( $\geq 4$ on the 11-point NRS) or $\geq 40$ mm on 100-mm VAS.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (14 weeks after treatment started).
<b>Intervention 1</b>	Pregabalin 600 mg/d Administered daily in 2 divided doses
<b>Participants (n)</b> <b>Drop-outs (n)</b>	186 Completed study: 121/186
<b>Intervention 2</b>	Pregabalin 450 mg/d Administered daily in 2 divided doses
<b>Participants (n)</b> <b>Drop-outs (n)</b>	182 Completed study: 133/182
<b>Intervention 2</b>	Pregabalin 300 mg/d Administered daily in 2 divided doses
<b>Participants (n)</b> <b>Drop-outs (n)</b>	184 Completed study: 123/184
<b>Comparison</b>	Placebo Administered daily in 2 divided doses
<b>Participants (n)</b> <b>Drop-outs (n)</b>	184 Completed study: 141/184
<b>Outcomes</b>	FIQ - total score, NRS – intensity, Subscales fr MOS - Sleep Scale: "sleep disturbance", NRS - diary – sleep quality, Patient global assessment (PGI) PGI-change
<b>Comments</b>	

## Studier inom psykologisk behandling

### KBT jämfört med väntelista eller sedvanlig vård

#### Alda 2011

<b>Author</b>	Alda
<b>Year</b>	2011
<b>Country</b>	Spain
<b>Ref #</b>	[7]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Primary health-care centers
<b>Recruitment</b>	Patients were consecutively recruited by doctors working in primary carecentres until the required sample size was attained, with-out a quota of patients assigned from each center.
<b>Population</b>	Adult (18 to 65 years) with fibromyalgia according to ACR-90.
<b>Inclusion criteria</b>	Able to understand and read Spanish, had undergone no psychological treatment during the preceding two years, were receiving no pharmacological treatment at that time or were willing to discontinue it for two weeks before the start of the study.
<b>Follow up</b>	End of treatment (9 weeks) and 6 months after start of treatment.
<b>Intervention 1</b>	CBT-pain 10 sessions during a period of 10 to 12 wks. Delivered in group.
<b>Participants (n)</b>	57
<b>Drop-outs (n)</b>	Completed post-treatment: 56/57 Completed 6 month follow up: 49/57
<b>Comparison</b>	Waitlist control
<b>Participants (n)</b>	55
<b>Drop-outs (n)</b>	Completed post-treatment: 53/55 Completed 6 month follow up: 46/55
<b>Outcomes</b>	FIQ - total score, EQ-5D VAS, VAS – intensity, Hamilton Rating Scale for depression (HAM-D) 17-item version, Pain Catastrophising Scale (PCS) Total score plus 4 subscales
<b>Comments</b>	ITT population included participants with baseline and data from at least one follow-up assessment. We assumed to be participants with post treatment follow-up, as follow-up data should be available for at least this fraction of participants (CBT n= 56, waitlist n=53).

#### Castel 2012

<b>Author</b>	Castel
<b>Year</b>	2012
<b>Country</b>	Spain
<b>Ref #</b>	[8]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Not stated
<b>Recruitment</b>	Not stated
<b>Population</b>	FM diagnosis (ACR-90). 18 – 65 years or older.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (week 14), 3, and 6 months post treatment.
<b>Intervention 1</b>	Multicomponent CBT 14 sessions, 12 in group and 2 individual sessions

<b>Participants (n)</b> <b>Drop-outs (n)</b>	34 Completed post-treatment: 31/34 Completed 3 month follow up: 32/34 Completed 6 month follow up: 26/34
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Waitlist control 30 Completed post-treatment: 29/30 Completed 3 month follow up: 23/30 Completed 6 month follow up: 22/30
<b>Outcomes</b>	FIQ - total score, NRS – intensity, Coping Strategies Questionnaire (CSQ) Subscale: Pain catastrophizing, MOS - Sleep Scale Subscales: 1) Quantity of sleep 2) Sleep problems,
<b>Comments</b>	

**Falcão 2008**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Falcão 2008 Brazil [9]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Research setting (University clinic), outpatients Patients were recruited from rheumatology outpatient clinics.
<b>Population</b>	Adult (18-65 years) women with fibromyalgia according to ACR.
<b>Inclusion criteria</b>	Patients had not received any kind of treatment for FM.
<b>Follow up</b>	End of treatment (10 weeks) and 3 months after end of treatment.
<b>Intervention 1</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	CBT-pain Routine medical visits and CBT once a week for 10 weeks, in group. 30 Completed post-treatment: 25/30 Completed 3 month follow up: 25/30
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Waitlist control Routine medical visits once a week for 10 weeks 30 Completed post-treatment: 26/30 Completed 3 month follow up: 26/30
<b>Outcomes</b>	FIQ - total score, SF-36 8 subscales, VAS – intensity, Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI) – State,
<b>Comments</b>	9 of 60 excluded from analysis

**Karlsson 2015**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Karlsson 2015 Sweden [10]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Primary health-care centers Participants recruited via newspaper and local FM association
<b>Population</b>	Adult (18 to 64 years) with fibromyalgia according to ACR-90.

<b>Inclusion criteria</b>	Being Swedish speaking.
<b>Follow up</b>	6 and 12 months after start of treatment. Wait-list control group moved to open-label active treatment after 6 months and followed up at 18 months.
<b>Intervention 1</b>	CBT-pain 20 weekly sessions (3 hour per session) over 5 months. Three booster sessions over the next 6 months (total duration of the intervention: 11 months). Group delivery (5-7 women). Home assignments.
<b>Participants (n)</b> <b>Drop-outs (n)</b>	24 Completed 6 month follow up: 23/24 Completed 12 month follow up: 24/24
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Waitlist control 24 Completed 6 month follow up: 24/24 Completed 12 month follow up: 22/24 (6 months after start of active treatment) Completed 18 month follow up: 22/24
<b>Outcomes</b>	West Haven-Yale Multidimensional Pain Inventory (MPI) Subscale: Pain severity Montgomery-Åsberg Depression Rating Scale – self-reported (MADR-S)
<b>Comments</b>	

**McCrae 2019**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	McCrae 2019 USA [11]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Research setting (University clinic), outpatients Participants were recruited from rheumatology and sleep clinics at the University of Florida and from the surrounding area through community advertisements.
<b>Population</b>	FM (ACR-90) with pain for at least 6 months and chronic insomnia. 18 years or older, willing to undergo randomization.
<b>Inclusion criteria</b>	Able to read and understand English.
<b>Follow up</b>	End of treatment (8 weeks) and 6 months after start of treatment.
<b>Intervention 1</b>	CBT-pain 8 individual sessions
<b>Participants (n)</b> <b>Drop-outs (n)</b>	37 Received intervention: 30/37 Completed post-treatment: 30/37 Completed 6 month follow up: 27/37
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Waitlist control 37 Received intervention: 37/37 Completed post-treatment: 28/37 Completed 6 month follow up: 23/37
<b>Outcomes</b>	VAS – intensity, Beck Depression Inventory (BDI), Dysfunctional Beliefs and Attitudes about Sleep (DBAS) Total score (VAS 1-10), Pain Disability Index (PDI) Total score,
<b>Comments</b>	



**Vallejo 2015**

<b>Author</b>	Vallejo
<b>Year</b>	2015
<b>Country</b>	Spain
<b>Ref #</b>	[12]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Research setting (University clinic)
<b>Recruitment</b>	Patients at Rheumatology unit.
<b>Population</b>	18 years or older with fibromyalgia according to ACR-90.,
<b>Inclusion criteria</b>	Adequate reading comprehension and access to and ability to use a computer.
<b>Follow up</b>	There were 2 assessment points for the WL group (i.e., baseline and post-treatment) and 5 for the CBT group (i.e., baseline, post-treatment and 3 follow-up assessments at 3, 6, and 12 months).
<b>Intervention 1</b>	CBT
<b>Participants (n)</b>	10 weekly sessions (120 minutes/session). Delivered in group. Homework assignments.
<b>Drop-outs (n)</b>	20 Completed post-treatment: 20/20 Completed follow-up at 3, 6, and 12 months: 17/20
<b>Intervention 2</b>	iCBT
<b>Participants (n)</b>	A Web application with a 10-week session structure. Individual delivery.
<b>Drop-outs (n)</b>	20 Completed post-treatment: 20/20 Completed follow-up at 3, 6, and 12 months: 16/20
<b>Comparison</b>	Waitlist control
<b>Participants (n)</b>	20
<b>Drop-outs (n)</b>	Completed post-treatment: 20/20
<b>Outcomes</b>	FIQ - total score Beck Depression Inventory (BDI), Hospital Anxiety and Depression Score (HADS) Total score, Pain Catastrophising Scale (PCS) 4 subscales, Chronic Pain Self-efficacy Scale (CPSS or CPSE) Total score och 3 subscales, Chronic Pain Coping Inventory (CPCI) Total score
<b>Comments</b>	

**Woolfolk 2012**

<b>Author</b>	Woolfolk
<b>Year</b>	2012
<b>Country</b>	USA
<b>Ref #</b>	[13]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Academic medical clinic.
<b>Recruitment</b>	Participants were referred to the study by their treating rheumatologists.
<b>Population</b>	Adult (18 to 64 years) with fibromyalgia according to ACR-90.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (3 months) and 9 months after start of treatment.
<b>Intervention 1</b>	Affective CBT (ACBT) + Treatment as usual
<b>Participants (n)</b>	10 sessions over 3 months. Individual delivery.
<b>Drop-outs (n)</b>	38 Completed post-treatment: 34/38 Completed 9 month follow up: 32/38
<b>Comparison</b>	Treatment as usual
<b>Participants (n)</b>	Content of TAU not given. 38

<b>Drop-outs (n)</b>	Completed post-treatment: 35/38 Completed 9 month follow up: 32/38
<b>Outcomes</b>	SF-36 Subscale: physical function, VAS – intensity, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Chronic Pain Self-efficacy Scale (CPSS eller CPSE) Total score
<b>Comments</b>	

## KBT jämfört med annan intervention

### Lumley 2017

<b>Author</b>	Lumley
<b>Year</b>	2017
<b>Country</b>	USA
<b>Ref #</b>	[14]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Flyers sent to rheumatologists, advertisements in the community, announcements to FM patient associations, and informational workshops.
<b>Recruitment</b>	
<b>Population</b>	
<b>Inclusion criteria</b>	FM as defined by the 1990 or 2011 criteria of the American College of Rheumatology (ACR)
<b>Follow up</b>	Post treatment (2 weeks after last session) och 6 months post treatment.
<b>Intervention 1</b>	Emotional Awareness and Expression Therapy
<b>Participants (n)</b>	Eight, 90-minute, weekly sessions.
<b>Drop-outs (n)</b>	79 Post treatment assessment: 74/79 6 months follow up: 70/79
<b>Intervention 2</b>	CBT
<b>Participants (n)</b>	Eight, 90-minute, weekly sessions.
<b>Drop-outs (n)</b>	75 Post treatment assessment: 69/75 6 months follow up: 66/75
<b>Comparison</b>	Fibromyalgia Education
<b>Participants (n)</b>	Eight, 90-minute, weekly sessions.
<b>Drop-outs (n)</b>	76 Post treatment assessment: 73/76 6 months follow up: 72/76
<b>Outcomes</b>	FIQ-R Total score and subscales, SF-12 Subscale: Physical functioning, CES-D, The Generalized Anxiety Disorder (GAD-7) Total score, Pittsburgh Sleep Quality Index (PSQI) Total score and subscales, Patient reported outcomes measurement information system (PROMIS) Fatigue short form Multiple Ability Self-Report Questionnaire (MASQ) Total score
<b>Comments</b>	

**ACT jämfört med väntelista eller sedvanlig vård****Luciano 2014**

<b>Author</b>	Luciano
<b>Year</b>	2014
<b>Country</b>	Spain
<b>Ref #</b>	[15]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Primary health care centers.
<b>Recruitment</b>	Patients recruited from primary health care centers
<b>Population</b>	Adult (18-56 years) patients with fibromyalgia according to ACR 1990.
<b>Inclusion criteria</b>	Could speak and read Spanish fluently, with no pharmacological treatment (or agreed to discontinue use to participate in the study) and no previous psychological treatment during the previous year.
<b>Follow up</b>	End of treatment (3 months) and 6 months after start of treatment
<b>Intervention 1</b>	GACT (Group Acceptance and Commitment Therapy) Eight 2 1/2 hour long structured sessions. Delivered in group. Home exercises assigned (15 to 30 minutes/day).
<b>Participants (n)</b>	51
<b>Drop-outs (n)</b>	Completed post-treatment: 46/51 Completed 6 month follow up: 45/51
<b>Comparison</b>	Waitlist No active treatment
<b>Participants (n)</b>	53
<b>Drop-outs (n)</b>	Completed post-treatment: 50/53 Completed 6 month follow up: 47/53
<b>Outcomes</b>	FIQ Total score, EQ-5D, VAS – intensity, Hospital Anxiety and Depression Score (HADS) Subscales: 1) Depression 2) Anxiety, Pain Catastrophising Scale (PCS) Total score, The Chronic Pain Acceptance Questionnaire (CPAQ) Total score
<b>Comments</b>	

**Simister 2018**

<b>Author</b>	Simister
<b>Year</b>	2018
<b>Country</b>	Canada
<b>Ref #</b>	[16]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Web-based intervention
<b>Recruitment</b>	Recruitment via local clinics, patient organisations and advertisement.

<b>Population</b>	Age 18 years and older, formal diagnosis of FM, and self-reported pain intensity rating of at least 4 of 10 on the basis of a 0 to 10 rating scale (0 representing no pain).
<b>Inclusion criteria</b>	Participants were also screened using the diagnostic criteria according to Wolfe to ensure they met criteria for FM.
<b>Follow up</b>	End of treatment (2 months) and 5 months after start of treatment
<b>Intervention 1</b>	Online ACT-program plus Treatment as usual Distance delivery (internet-online) to be completed within 2 months. ACT consisted of 7 modules patients were encouraged to complete 1/wk. Individual delivery. Home assignments.
<b>Participants (n)</b>	33
<b>Drop-outs (n)</b>	Completed post-treatment: 27/33 Completed 6 month follow up: 25/33
<b>Comparison</b>	Treatment as usual Continued current treatment regime.
<b>Participants (n)</b>	34
<b>Drop-outs (n)</b>	Completed post-treatment: 31/34 Completed 6 month follow up: 25/34
<b>Outcomes</b>	FIQ-R Total score, McGill Pain questionnaire (MPG) Short form (SF-MPQ), CES-D Depression, Pittsburgh Sleep Quality Index (PSQI), CPAQ-R Total score
<b>Comments</b>	

## MBSR jämfört med väntelista eller sedvanlig vård

### Cejudo 2019

<b>Author</b>	Cejudo
<b>Year</b>	2019
<b>Country</b>	Spain
<b>Ref #</b>	[17]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Not stated
<b>Recruitment</b>	Volunteers from the Association of Relatives and Affected by Fibromyalgia of the province of Ciudad Real.
<b>Population</b>	Adult (>18 years) women with fibromyalgia (ACR).
<b>Inclusion criteria</b>	commit to the daily practice of mindfulness, and not be currently receiving mindfulness training
<b>Follow up</b>	End of treatment (20 weeks), and 6 months post-treatment.
<b>Intervention 1</b>	MBI (Mindfulness based intervention) 1-hour group session once per week for 20 weeks.
<b>Participants (n)</b>	59
<b>Drop-outs (n)</b>	Follow up at 20 weeks (end of treatment): 53/59 Follow up at 6 months post treatment: 52/59
<b>Comparison</b>	Wait list The treatment of the Control Group was focused on psychoeducation and included information on common symptoms in FM and advice on self-care.
<b>Participants (n)</b>	58
<b>Drop-outs (n)</b>	Follow up at 20 weeks (end of treatment): 51/58 Follow up at 6 months post treatment: 49/58
<b>Outcomes</b>	Satisfaction w life Scale (SWLS) - går att väga samman med EQ-5D
<b>Comments</b>	

### Schmidt 2011

<b>Author</b>	Schmidt
<b>Year</b>	2011
<b>Country</b>	Germany
<b>Ref #</b>	[18]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	University hospital.
<b>Recruitment</b>	Patient recruitment through patient self-help groups, media and medical practitioners at a pain clinic located within a university hospital.
<b>Population</b>	Women 18–70 years of age who currently had fibromyalgia (ACR).
<b>Inclusion criteria</b>	Command of the German language and motivation to participate.
<b>Follow up</b>	End of treatment (8 wks). Weeks three and seven after end of treatment.
<b>Intervention 1</b>	Mindfulness based stress reduction (MBSR) 8 wks duration. 7 (2.5 hr long) sessions and 1 all-day session on a weekend. Delivered in groups of 12.
<b>Participants (n)</b>	59
<b>Drop-outs (n)</b>	Received intervention: 53/59 Follow up at 3 weeks post treatment: 45/59 Follow up at 7 weeks post treatment: 47/59
<b>Intervention 2</b>	Active control 8 wks duration. Delivered similar to MBSR in time. Delivered in groups.
<b>Participants (n)</b>	59
<b>Drop-outs (n)</b>	Received intervention: 56/59

	Follow up at 3 weeks post treatment: 51/59 Follow up at 7 weeks post treatment: 49/59
<b>Comparison</b>	Wait list
<b>Participants (n)</b>	59
<b>Drop-outs (n)</b>	Follow up at 3 weeks post treatment: 52/59 Follow up at 73 weeks post treatment: 56/59
<b>Outcomes</b>	FIQ - total score, Quality of Life Profile for the Chronically ill (PLC) Total score, Pain Perception Scale (PPS) Subscales (sensory and affective pain), CES-D, State Trait Anxiety Inventory (STAI) Subscale: Trait, Pittsburgh Sleep Quality Index (PSQI) Total score, Giessen Complaint Questionnaire (GCQ)
<b>Comments</b>	

### Sephton 2007

<b>Author</b>	Sephton
<b>Year</b>	2007
<b>Country</b>	USA
<b>Ref #</b>	[19]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	University
<b>Recruitment</b>	Patients recruited through notices in newspapers and TV.
<b>Population</b>	Adult (>18 years) women with fibromyalgia (ACR).
<b>Inclusion criteria</b>	Able to attend a group that met weekly.
<b>Follow up</b>	8 wks (end of treatment), and 2 months post-treatment.
<b>Intervention 1</b>	Mindfulness-based stress reduction (MBSR) 8 weekly 2.5 hour long sessions. Group delivery. Home assignments (ca 30-45 minutes/day encouraged).
<b>Participants (n)</b>	51
<b>Drop-outs (n)</b>	Received intervention: 42/51 Follow up at 2 months post treatment: 41/51 Participants included in analysis: 51/51
<b>Comparison</b>	Wait list
<b>Participants (n)</b>	40
<b>Drop-outs (n)</b>	Follow up at 2 months post treatment: 27/40 Participants included in analysis: 39/40
<b>Outcomes</b>	Beck Depression Inventory (BDI) Total score and cognitive and somatic subscales
<b>Comments</b>	

### Perez-Aranda 2019

<b>Author</b>	Perez-Aranda
<b>Year</b>	2019
<b>Country</b>	Spain
<b>Ref #</b>	[20]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Rheumatology Clinic
<b>Recruitment</b>	Recruitment from a rheumatology clinic.
<b>Population</b>	Patients 18–65 years of age who currently have fibromyalgia (ACR).
<b>Inclusion criteria</b>	Able to understand Spanish language and provided informed consent to participate.

<b>Follow up</b>	2 months (end of treatment) and 12 months (10 months after end of treatment)
<b>Intervention 1</b>	Mindfulness-based stress reduction (MBSR) + TAU Treatment period: 8 wks. Two-hour long sessions, 1 per week plus a half day (6 h) long retreat. Delivered in group (ca 15 patients/group).
<b>Participants (n)</b>	75
<b>Drop-outs (n)</b>	Follow up at end of treatment: 68/75 Follow up at 2 months post treatment: 44/75
<b>Comparison</b>	TAU (Wait list) No active treatment
<b>Participants (n)</b>	75
<b>Drop-outs (n)</b>	Follow up at end of treatment: 68/75 Follow up at 2 months post treatment: 43/75
<b>Outcomes</b>	FIQ-R - total score (100) EQ-5D-5L and EQ-VAS, Hospital Anxiety and Depression Score (HADS) Subscale: Depression Perceived Stress Scale (PSS 10) Total score Pain Catastrophising Scale (PCS) Total score Multidimensional Inventory of Subjective Cognitive Impairment (MISCI) PGI-C Förändring PSI-C Item: function
<b>Comments</b>	



## MBSR jämfört med annan intervention

### VanGordon 2017

<b>Author</b>	VanGordon
<b>Year</b>	2017
<b>Country</b>	UK
<b>Ref #</b>	[21]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Multiple sites. Separate training rooms utilized by a meditation centre and GP surgery
<b>Recruitment</b>	Talks at FMS self-help groups, posters in GP surgeries, and emails sent to members of FMS support groups.
<b>Population</b>	Male and female aged between 18 and 65 years, being able to read and write using the English language with a current diagnosis of FMS (as confirmed by a letter from a general practitioner [GP], rheumatologist, or hospital pain consultant).
<b>Inclusion criteria</b>	Not currently undergoing formal psychotherapy, no changes in psychopharmacology type or dosage 1-month prior to intervention (although stable prescription medication was permitted), and not currently practicing mindfulness or meditation.
<b>Follow up</b>	8 wks and 6 months
<b>Intervention 1</b>	Meditation Awareness training
<b>Participants (n)</b>	8 (2 hr long) workshops over 8 wks. Delivered in group. 74
<b>Drop-outs (n)</b>	Completed post intervention assessment: 54/74 Completed 6 months follow-up assessment: 45/74
<b>Intervention 2</b>	Cognitive behavioural theory for groups
<b>Participants (n)</b>	8 (2 hr long) workshops over 8 wks. Delivered in group. 74
<b>Drop-outs (n)</b>	Completed post intervention assessment: 52/74 Completed 6 months follow-up assessment: 40/74
<b>Outcomes</b>	FIQ-R - total score, McGill Pain questionnaire (MPQ), Short Form (SF-MPQ), Depression, Anxiety, and Stress Scale (DASS), NRS - Sleep quality,
<b>Comments</b>	

## Psykoedukativa insatser jämfört med väntelista eller sedvanlig vård

### Barrenengoa-Cuadra 2021

<b>Author</b>	Barrenengoa-Cuadra
<b>Year</b>	2021
<b>Country</b>	Spain
<b>Ref #</b>	[22]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Primary care setting.
<b>Recruitment</b>	Databases of patients with FM included in the waiting lists for appointments in five primary health care centres.
<b>Population</b>	Male and female patients aged 18 years or older who had been previously diagnosed with FM by their attending physician in any health care setting.
<b>Inclusion criteria</b>	
<b>Follow up</b>	After treatment (1 month) and follow-up visits at 6 and 12 months.
<b>Intervention 1</b>	Intervention group The intervention consisted of six 2-hr weekly classes taught by a multidisciplinary team of two or three experienced therapists trained in teaching educational interventions to patients with FM, followed by a seventh reinforcement class a month later
<b>Participants (n)</b>	70
<b>Drop-outs (n)</b>	Completed 1 month follow up: 70/70 Completed 12 month follow up: 68/70
<b>Comparison</b>	Treatment as usual The usual treatment for patients with FM is mainly pharmacological and adjusted to the symptomatic profile of each individual patient, mostly including antidepressants, antiepileptics and opioid and nonopioid analgesics.
<b>Participants (n)</b>	70
<b>Drop-outs (n)</b>	Completed 1 month follow up: 69/70 Completed 12 month follow up: 67/70
<b>Outcomes</b>	FIQ - total score, Brief Pain Inventory: 1) BPI - subscale: severity 2) BPI - subscale: interference, HADS: depression, HADS – anxiety, Pain Catastrophising Scale (PCS), Healthy Assessment Questionnaire (HAQ)
<b>Comments</b>	

### Luciano 2011

<b>Author</b>	Luciano
<b>Year</b>	2011
<b>Country</b>	Spain
<b>Ref #</b>	[23, 24]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	general practices
<b>Recruitment</b>	Patients recruited through general practitioners office
<b>Population</b>	Patients aged between 18 and 75 years contactable by telephone, and who met the diagnostic criteria of FM established by the ACR.
<b>Inclusion criteria</b>	
<b>Follow up</b>	At end of treatment (2 months.)
<b>Intervention 1</b>	Psychoeducational program + TAU

<b>Participants (n)</b> <b>Drop-outs (n)</b>	Nine 2-hour sessions delivered over a 2-month period (1 afternoon session per week). 5 educative sessions and 4 autogenic training sessions. 108 Followed up at post-treatment: 92/108
<b>Comparison</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Treatment as Usual In general practice, the treatment provided is mainly pharmacologic and is adjusted to the symptomatic profile of the patient. In addition, counselling about aerobic exercise adjusted to patients' physical limitations is usually provided. 108 Followed up at post-treatment: 93/108
<b>Outcomes</b>	FIQ - total score and FIQ - 7 subscales,
<b>Comments</b>	

**Musekamp 2019**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Musekamp 2019 Germany [25]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>  <b>Population</b>  <b>Inclusion criteria</b>  <b>Follow up</b>	Randomized controlled trial Inpatient rehabilitation centres. Patients recruited through fliers, advertisements and presentations at fibromyalgia support groups  Eligible for participation were adult patients with FMS (ICD-10: M79.7), evaluated by the physicians at admission.   At end of treatment (6 weeks post randomization), follow up at 6 and 12 months.
<b>Intervention 1</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Intervention Group Six sessions of 90 min each plus one optional preparing session. Topics were diagnosis and treatment of FMS, coping strategies for pain and stress and promotion of physical activity. 295 Received allocated intervention: 281 Follow up end of treatment: 252/281 Follow up at 6 months: 224/281 Follow up at 12 months: 201/281
<b>Comparison</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Treatment as usual Information about FMS and coping with pain. In contrast to the intervention condition, usual care education did not consider the updated evidence on FMS and was less self-management oriented. 316 Received allocated intervention: 302 Follow up end of treatment: 265/302 Follow up at 6 months: 244/302 Follow up at 12 months: 222/302
<b>Outcomes</b>	FIQ - health impairment, Patient Health Questionnaire (PHQ) HQ 4, subscales: 1) Depression, 2) Anxiety
<b>Comments</b>	

## Studier inom fysisk aktivitet och manuella behandlingar

### Guidad fysisk aktivitet jämfört med väntelista, sedvanlig behandling eller annan minimal intervention

#### Baptista 2012

Author	Baptista
Year	2012
Country	Brazil
Ref #	[26]
Study design	Randomized controlled trial
Setting	Not stated
Recruitment	Patients were selected from the Rheumatology outpatient clinic
Population	Diagnosis of fibromyalgia based on the criteria of the American College of Rheumatology (1); female gender; age between 18 and 65 years.
Inclusion criteria	
Follow up	At 16 weeks (T16) and 32 weeks (T32) following the initial evaluation.
Intervention 1	Dance One-hour belly dance classes twice a week for 16 weeks. Maximum of eight students per class.
Participants (n)	40
Drop-outs (n)	Completed 16 weeks follow up: 39/40 Completed 32 weeks follow up: 38/40
Comparison	Control
Participants (n)	40
Drop-outs (n)	Completed 16 weeks follow up: 39/40 Completed 32 weeks follow up: 37/40
Outcomes	FIQ - total score, SF-36 8 subscales, VAS – intensity, Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory (STAI) "Part 1 and 2" - state and trait.
Comments	

#### Carson 2010

Author	Carson
Year	2010
Country	USA
Ref #	[27, 28]
Study design	Randomized controlled trial
Setting	Exercise studio at university school of nursing.
Recruitment	The participants were all patients referred to a university tertiary care center.
Population	Diagnosis of FM (ACR-90) for at least 1 year, female, stable pharmacologic and/or non-pharmacologic treatment for FM for at least 3 months.
Inclusion criteria	
Follow up	Post treatment (8 weeks) and after 3 months (only intervention group).
Intervention 1	Yoga of awareness Eight once-per-week 120 min group classes (7–12 patients per group). 40 min stretching, 25 min mindfulness, 10 min breathing techniques, 20 min how to apply yoga for coping, 25 min group discussions.
Participants (n)	25
Drop-outs (n)	Received treatment: 22/25 Follow up post treatment: 22/25

	Follow up 3 months post treatment: 21/25
<b>Comparison</b>	Wait list Routine medical care for FM. After the post-treatment assessment, these patients were invited to participate in the yoga program.
<b>Participants (n)</b>	28
<b>Drop-outs (n)</b>	Follow up post treatment: 26/28
<b>Outcomes</b>	FIQ-R - total score and 9 Subscales, Diary: Pain, Diary: Emotional distress, Diary: Fatigue, PGI-I Overall improvement, The Chronic Pain Acceptance Questionnaire (CPAQ) Total score och subscales: 1) Activity engagement 2) Pain willingness, Coping Strategies Questionnaire (CSQ) Subscale: 1) Pain catastrophizing Vanderbilt Multidimensional Pain Coping Inventory (VMPCI) 10 subscales - adaptive resp maladaptive coping
<b>Comments</b>	

**DaCosta 2005**

<b>Author</b>	DaCosta
<b>Year</b>	2005
<b>Country</b>	Canada
<b>Ref #</b>	[29]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Not stated.
<b>Recruitment</b>	From hospital or community rheumatologists, directly or through letters of invitation and through newspaper advertisements.
<b>Population</b>	Adult women w fibromyalgia
<b>Inclusion criteria</b>	
<b>Follow up</b>	12 wks (post-treatment), 6 and 12 months from study entry.
<b>Intervention 1</b>	Home based exercise program The patient met with a physiotherapist for 4 sessions over the 12 wks for help and instruction on aerobic exercise. Patients were provided w a heart rate monitor and were asked to complete an FM symptom measure and to record exercise activity weekly during the 12-week intervention phase and monthly thereafter.
<b>Participants (n)</b>	39
<b>Drop-outs (n)</b>	Completed Baseline questionnaires: 39/39 Completed post intervention (3 months): 33/39 Completed 6 months follow up: 33/39 Completed 12 months follow up: 28/39
<b>Comparison</b>	Treatment as usual Participants were asked to complete an FM symptom measure and to record exercise activity weekly during the 12-week intervention phase and monthly thereafter.
<b>Participants (n)</b>	41
<b>Drop-outs (n)</b>	Completed Baseline questionnaires: 40/41 Completed post intervention (3 months): 36/41 Completed 6 months follow up: 36/41 Completed 12 months follow up: 33/41
<b>Outcomes</b>	FIQ - total score, VAS – intensity 1 Upper body 2) Lower body The Symptom Checklist-90—Revised (SCL-90-R)
<b>Comments</b>	

**Fontaine 2010**

<b>Author</b>	Fonataine
<b>Year</b>	2010
<b>Country</b>	USA

<b>Ref #</b>	[30, 31]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Participants were recruited from the Arthritis Center and Rheumatology clinics, by advertisements in the Arthritis newsletter, newspaper advertisements, and via clinical trial recruitment websites.
<b>Population</b>	Adults aged 18 years or older who met American College of Rheumatology diagnostic criteria for FM.
<b>Inclusion criteria</b>	At enrolment, participants were not meeting the US Surgeon General's 1996 recommendation for physical activity for the previous six months (that is, not engaging in either moderate-intensity physical activity for $\geq 30$ minutes on $\geq$ five days per week or vigorous physical activity $\geq$ three times per week for $\geq 20$ minutes each time during the previous month).
<b>Follow up</b>	Post intervention (12 weeks), 6 months and 12 months.
<b>Intervention 1</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Lifestyle physical activity Sex 60-minute group sessions over 12 weeks. First week prescribed 15 minutes, above usual level, of accumulated moderate-intensity LPA five to seven days a week and asked to increase the daily duration of LPA by five minutes each week. 46 Completed intervention: 40/46 Completed 6 and 12 months follow up: 30/46
<b>Intervention 2</b> <b>Participants (n)</b>  <b>Drop-outs (n)</b>	Fibromyalgia education Three 90- 120-minute meetings once per month for 12 weeks. Education, Q&A, Social support. n. The final session of FME presented information on exercise and physical activity, but no specific recommendations or prescription concerning exercise was given. 38 Completed intervention: 33/38 Completed 6 and 12 months follow up: 23/38
<b>Comparison</b>	Not applicable
<b>Outcomes</b>	FIQ - total score, VAS – intensity, CES-D, Fatigue Severity Scale (FSS),
<b>Comments</b>	For 6- and 12-months n analyzed = 53.

**Haak 2008**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Haak 2008 Sweden [32]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial The subjects were recruited from the local press, Patient's Association for Fibromyalgia, national care centres (primary care, physiotherapists, family doctors) and the Swedish National Insurance Scheme.
<b>Population</b>	Female, at least 18 years old with fibromyalgia diagnosis since at least 6 months
<b>Inclusion criteria</b>	
<b>Follow up</b>	Post treatment. 4 months follow up (only intervention)
<b>Intervention 1</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Qigong 9 group sessions during 7 weeks for a total of 11.5 hours 29 Follow up post treatment: 28/29 Follow up 4 months post treatment: 28/29
<b>Comparison</b>	Wait list Waiting list for 7 weeks, thereafter qigong 9 group sessions during 7 weeks for a total of 11.5 hours.

<b>Participants (n)</b>	28
<b>Drop-outs (n)</b>	Follow up post treatment: 28/28
<b>Outcomes</b>	The World Health Organization Quality of Life BREF (WHOQOL-BREF) Total score och subscales: 1) Psychological health, 2) Physical health, Diary 1) pain intensity 2) Inconvenience due to pain 3) Ability to control, Visual Numerological Scale (VNS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI) – state, Diary: Sleep quality, Visual Numerological Scale (VNS), Diary: 1) Restoration after sleep, 2) Energy level, 3) Ability to concentrate, Visual Numerological Scale (VNS)
<b>Comments</b>	

**Mannerkorpi 2010**

<b>Author</b>	Mannerkorpi
<b>Year</b>	2010
<b>Country</b>	Sweden
<b>Ref #</b>	[33]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	
<b>Recruitment</b>	Newspaper advertisements, at health care centres or from participation in an earlier study.
<b>Population</b>	Women aged 20 to 60 years with fibromyalgia, defined by the ACR 1990 criteria [2]: a history of long-lasting generalized pain and pain in at least 11 of 18 tender points examined by manual palpation.
<b>Inclusion criteria</b>	Ability to manage a bicycle test at 50 watts or more, and interest in exercising outdoors twice a week for 15 weeks.
<b>Follow up</b>	16 weeks (post 15-week intervention) and 6 months.
<b>Intervention 1</b>	Nordic walking group Supervised exercise sessions twice a week for 15 weeks. The target was to achieve 20 minutes of moderate-to-high intensity exercise.
<b>Participants (n)</b>	34
<b>Drop-outs (n)</b>	Received intervention: 29/34 Post treatment analysis: 29/34 Long time follow up analysis: 28/34
<b>Intervention 2</b>	Low intensive walking group Supervised exercise sessions once a week for 15 weeks. Walked at a low intensity level.
<b>Participants (n)</b>	33
<b>Drop-outs (n)</b>	Received intervention: 28/33 Post treatment analysis: 29/33 Long time follow up analysis: 26/33
<b>Comparison</b>	Not applicable.
<b>Outcomes</b>	FIQ - total score Subscale: pain, Multidimensional Fatigue Inventory (MFI) Subscales: 1) General fatigue 2) Physical fatigue 3) Reduced activity 4) Reduced motivation 5) Mental fatigue
<b>Comments</b>	

**Paulucci 2016**

<b>Author</b>	Paulucci
<b>Year</b>	2016
<b>Country</b>	Italy
<b>Ref #</b>	[34]
<b>Study design</b>	
<b>Setting</b>	At a physical medicine and rehabilitation unit.

<b>Recruitment</b>	
<b>Population</b>	FM (ACR 1990 and 2010), diagnosis established by the patient's rheumatologist. Age 18-60 years. A score of >5 on the visual analog scale (VAS), in the last three months.
<b>Inclusion criteria</b>	Tenderness of at least 2 of the 4 tender points on the back; and baseline condition of sedentary lifestyle with no or irregular physical activity.
<b>Follow up</b>	At 5 weeks and 12 weeks following the initial evaluation.
<b>Intervention 1</b>	Physical Exercises
<b>Participants (n)</b>	21
<b>Drop-outs (n)</b>	Follow up 5 weeks:19/21 Follow up 12 weeks: 18/21
<b>Intervention 2</b>	Perceptual surfaces
<b>Participants (n)</b>	20
<b>Drop-outs (n)</b>	Follow up 5 weeks:19/20 Follow up 12 weeks: 18/20
<b>Comparison</b>	Control group
<b>Participants (n)</b>	21
<b>Drop-outs (n)</b>	Follow up 5 weeks:20/21 Follow up 12 weeks: 18/21
<b>Outcomes</b>	FIQ - total score and The Fibromyalgia Assessment Status (FAS) - total score, Health Assessment Questionnaire (HAQ) - total score
<b>Comments</b>	



## Fysioterapeutisk behandling – Guidad fysisk aktivitet jämfört med annan intervention

### Altan 2009

<b>Author</b>	Altan
<b>Year</b>	2009
<b>Country</b>	Turkey
<b>Ref #</b>	[35]
<b>Study design</b>	Randomized controlled trial.
<b>Setting</b>	Physical medicine and rehabilitation department.
<b>Recruitment</b>	Patients at rheumatology clinic.
<b>Population</b>	Women who had a diagnosis of fibromyalgia syndrome (FMS) according to the ACR.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (12 weeks) and 12 weeks after end of treatment (24 weeks).
<b>Intervention 1</b>	Pilates exercise program 1 hour 3 times a week for 12 weeks. The exercise program follows the basic principles of the Pilates method.
<b>Participants (n)</b>	25
<b>Drop-outs (n)</b>	Completed treatment, 12 weeks: 25/25 Follow up 24 weeks: Not stated
<b>Comparison</b>	Control group Home exercise/relaxation program and instructions to do this 1 hour 3 times a week for 12 weeks.
<b>Participants (n)</b>	25
<b>Drop-outs (n)</b>	Completed treatment, 12 weeks: 25/25 Follow up 24 weeks: Not stated
<b>Outcomes</b>	FIQ - total score, Nottingham Health Profile (NHP): Subscales combined in a summated score, VAS – intensity past wk,
<b>Comments</b>	

### Calandre 2009

<b>Author</b>	Calandre
<b>Year</b>	2009
<b>Country</b>	Spain
<b>Ref #</b>	[36]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	
<b>Recruitment</b>	Patients at pain unit or rehabilitation at university hospital.
<b>Population</b>	Patients were included if they were aged 18 years or older, had a diagnosis of fibromyalgia according to the current ACR criteria, and provided written informed consent to participate.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (6 weeks), 1 month and 3 months post treatment.
<b>Intervention 1</b>	Tai Chi 18 physiotherapy sessions of 60 minutes of duration performed 3 times a week during 6 weeks. Training was done in a pool with water heated at 36°C of temperature. Patients were taught the 16 movements of Tai Chi.
<b>Participants (n)</b>	42
<b>Drop-outs (n)</b>	Completed trial (6 weeks): 32/42 1 month follow up: 30/42 3 month follow up: 29/42
<b>Intervention 2</b>	Stretching

<b>Participants (n)</b> <b>Drop-outs (n)</b>	18 physiotherapy sessions of 60 minutes of duration performed 3 times a week during 6 weeks. Training was done in a pool with water heated at 36°C of temperature. Stretching was done with facilitating objects. 39 Completed trial (6 weeks): 34/39 1 month follow up: 32/39 3 month follow up: 28/39
<b>Outcomes</b>	FIQ - total score Subscales: 7 subscales, SF-36 Subscales: 1) Physical components 2) Mental components, Beck Depression Inventory (BDI) Total score and subscales: 1) Affective component 2) Somatic component, State-Trait Anxiety Inventory (STAI) Subscales: 1) State 2) Trait, Pittsburgh Sleep Quality Index (PSQI) - total score Subscales (7 subscales),
<b>Comments</b>	

**Kayo 2012**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Kayo 2012 Brazil [37]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b> <b>Population</b> <b>Inclusion criteria</b>	Randomized controlled trial  Patients at a Rheumatology Services at a Specialty Outpatient Clinic  30–55 years of age, diagnosed with fibromyalgia according ACR 1990 criteria.  Women who agreed to participate in an exercise program 3 times per week for 16 weeks, and to discontinue medication for Fibromyalgia 4 weeks before the start of the study (washout period), and who had at least 4 years of schooling.
<b>Follow up</b>	End of treatment (16 weeks) and follow up 12 weeks after treatment ended (28 weeks).
<b>Intervention 1</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Walking program Physical activity, walking, for about 60 min, 3 times per week for 16 weeks.  30 Completed treatment (16 weeks): 28/30 Follow up (28 weeks): 23/30
<b>Intervention 2</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Muscle-strengthening exercises Physical activity, 11 free active exercises, for about 60 min, 3 times per week for 16 weeks.  30 Completed treatment (16 weeks): 23/30 Follow up (28 weeks): 22/30
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Control Group 30 Completed treatment (16 weeks): 28/30 Follow up (28 weeks): 23/30
<b>Outcomes</b>	FIQ - total score, SF-36 Subscale: Bodily pain, VAS – intensity,
<b>Comments</b>	

**Richards 2002**

<b>Author</b>	Richards
<b>Year</b>	2002
<b>Country</b>	UK
<b>Ref #</b>	[38]
<b>Study design</b>	Randomised controlled trial
<b>Setting</b>	Group based classes took place at a "healthy living centre."
<b>Recruitment</b>	Hospital rheumatology outpatients
<b>Population</b>	Men and women aged 18-70 years who had fibromyalgia according to ACR1990 and were able to give informed consent
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (3 months), follow up at 6 months and 12 months.
<b>Intervention 1</b>	Exercise 1-hour long classes of up to 18 individuals twice weekly for 12 weeks. Individualised aerobic exercise programme, mostly walking on treadmills and cycling on exercise bicycles.
<b>Participants (n)</b>	69
<b>Drop-outs (n)</b>	End of treatment (3 months): 57/69 Follow up 6 months: Not stated Follow up 12 months: Not stated
<b>Comparison</b>	Relaxation 1-hour long classes of up to 18 individuals twice weekly for 12 weeks. Upper and lower limb stretches and relaxation techniques.
<b>Participants (n)</b>	67
<b>Drop-outs (n)</b>	End of treatment (3 months): 55/67 Follow up 6 months: Not stated Follow up 12 months: Not stated
<b>Outcomes</b>	FIQ - total score,
<b>Comments</b>	Analysed data on an intention to treat basis. Any missing follow up data was replaced with the last know value even if this was the baseline value.

**Wang 2010**

<b>Author</b>	Wang
<b>Year</b>	2010
<b>Country</b>	United States
<b>Ref #</b>	[39]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Tertiary care academic hospital.
<b>Recruitment</b>	Not stated.
<b>Population</b>	21 years of age or older and fulfilled the ACR 1990 diagnostic criteria for fibromyalgia.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (12 weeks) and follow up 24 weeks.
<b>Intervention 1</b>	Tai chi 60 minutes each and took place twice a week for 12 weeks, classical Yang style of tai chi.
<b>Participants (n)</b>	33
<b>Drop-outs (n)</b>	Completed 12 weeks evaluation: 32/33 Completed 24 weeks evaluation: 30/32
<b>Comparison</b>	Control intervention 60 minutes each and took place twice a week for 12 weeks, wellness education and stretching.
<b>Participants (n)</b>	33
<b>Drop-outs (n)</b>	Completed 12 weeks evaluation: 29/33 Completed 24 weeks evaluation: 29/33

<b>Outcomes</b>	FIQ - total score, SF-36 Subscales: 1) Physical components 2) Mental components, "Patient's global assessment", CES-D, Pittsburgh Sleep Quality Index (PSQI) - total score, Chronic Pain Self-efficacy Scale (CPSS) - total score,
<b>Comments</b>	

**Wang 2018**

<b>Author</b>	Wang
<b>Year</b>	2018
<b>Country</b>	United States
<b>Ref #</b>	[40]
<b>Study design</b>	Randomized comparative trial
<b>Setting</b>	Urban tertiary care academic hospital
<b>Recruitment</b>	Advertisements and enrolment through clinic.
<b>Population</b>	21 years or older and fulfilled the ACR 1990 and 2010 preliminary diagnostic criteria for fibromyalgia
<b>Inclusion criteria</b>	
<b>Follow up</b>	12, 24, and 52 weeks.
<b>Intervention 1</b>	Tai chi 1 session* 12 weeks. Each session 60 min. Warm-up and a review of tai chi principles, meditative movements, breathing techniques, and various relaxation methods.
<b>Participants (n)</b>	39
<b>Drop-outs (n)</b>	Completed week 12: 29/39 Completed week 24: 28/39 Completed week 52: 25/39
<b>Intervention 2</b>	Tai chi 2 session * 12 weeks. Each session 60 min. Warm-up and a review of tai chi principles, meditative movements, breathing techniques, and various relaxation methods.
<b>Participants (n)</b>	37
<b>Drop-outs (n)</b>	Completed week 12: 31/37 Completed week 24: 30/37 Completed week 52: 26/37
<b>Intervention 3</b>	Tai chi 1 session * 24 weeks. Each session 60 min. Warm-up and a review of tai chi principles, meditative movements, breathing techniques, and various relaxation methods.
<b>Participants (n)</b>	39
<b>Drop-outs (n)</b>	Completed week 12: 36/39 Completed week 24: 34/39 Completed week 52: 29/39
<b>Intervention 4</b>	Tai chi 2 session * 24 weeks. Each session 60 min. Warm-up and a review of tai chi principles, meditative movements, breathing techniques, and various relaxation methods.
<b>Participants (n)</b>	36
<b>Drop-outs (n)</b>	Completed week 12: 29/36 Completed week 24: 32/36 Completed week 52: 25/36
<b>Intervention 5</b>	Aerobic exercise 2 session * 24 weeks. Each session 60 min. Active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching.
<b>Participants (n)</b>	75
<b>Drop-outs (n)</b>	Completed week 12: 58/75 Completed week 24: 57/75 Completed week 52: 53/75
<b>Outcomes</b>	FIQ-R - total score,

	SF-36 Subscales: 1) Physical components 2) Mental components, Beck Depression Inventory-II (BDI-II), Hospital Anxiety and Depression Scale (HADS) Subscale: Depression, Hospital Anxiety and Depression Scale (HADS) Subscale: Anxiety, Pittsburgh Sleep Quality Index (PSQI) - total score, Health Assessment Questionnaire (HAQ) - total score, Patient's global assessment, Arthritis Self-Efficacy Scale (ASES) - total score, Coping Strategies Questionnaire (CSQ) - total score
<b>Comments</b>	

## Akupunktur

### Assefi 2005

<b>Author</b>	Assefi
<b>Year</b>	2005
<b>Country</b>	USA
<b>Ref #</b>	[41]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	8 private acupuncture practices
<b>Recruitment</b>	
<b>Population</b>	Adults 18 years of age or older. Fibromyalgia diagnosed by a physician. Pre-randomization global pain score of 4 or greater on a visual analogue scale.
<b>Inclusion criteria</b>	
<b>Follow up</b>	After 1, 4, 8, and 12 weeks of acupuncture treatment; and 3 and 6 months after completion of treatment
<b>Intervention 1</b>	Directed acupuncture for fibromyalgia twice weekly for 12 weeks (24 treatments)
<b>Participants (n)</b>	25
<b>Drop-outs (n)</b>	Completed study: 23/25
<b>Comparison 1</b>	Sham acupuncture for unrelated condition (control 1) twice weekly for 12 weeks (24 treatments)
<b>Participants (n)</b>	24
<b>Drop-outs (n)</b>	Completed study: 22/24
<b>Comparison 2</b>	Sham needling (control 2) twice weekly for 12 weeks (24 treatments)
<b>Participants (n)</b>	24
<b>Drop-outs (n)</b>	Completed study: 22/24
<b>Comparison 3</b>	Simulated acupuncture (control 3) twice weekly for 12 weeks (24 treatments)
<b>Participants (n)</b>	23
<b>Drop-outs (n)</b>	Completed study: 19/23
<b>Outcomes</b>	SF-36 Subscales: 1) Physical components 2) Mental components, VAS – intensity, VAS: 1) Fatigue 2) sleep quality
<b>Comments</b>	Completed study means completed Approximately participant drop out 13%, but not clearly stated in article.

### Targino 2008

<b>Author</b>	Targino
<b>Year</b>	2008
<b>Country</b>	Brazil
<b>Ref #</b>	[42]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Not stated.
<b>Recruitment</b>	By physicians from hospital.
<b>Population</b>	Female. Diagnosed according to the 1990 American College of Rheumatology (ACR) criteria. 20 to 70 years. VAS >4.
<b>Inclusion criteria</b>	Use antidepressant medicine.
<b>Follow up</b>	Post treatment (3 months after baseline). 6, 12 and 24 months after baseline.
<b>Intervention 1</b>	Acupuncture + standard care

<b>Participants (n)</b> <b>Drop-outs (n)</b>	Twenty 20-minute sessions twice weekly for 10 weeks. Acupuncture points employed were: Ex-HN-3 and bilateral LR3, LI4, PC6, GB34 and SP6 points. Chi sensation was sought. 12.5–75 mg of tricyclic antidepressants per day, oral instruction to walk for 30 min twice a week, to perform mental relaxation exercises for another 30 min. They were also told to perform twice-weekly stretching exercises. 34 Follow up 3 months: 34/34 Follow up 6 months: 34/34 Follow up 12 months: 34/34 Follow up 24 months: 32/34
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Standard care 12.5–75 mg of tricyclic antidepressants per day, oral instruction to walk for 30 min twice a week, to perform mental relaxation exercises for another 30 min. They were also told to perform twice-weekly stretching exercises. 24 Follow up 3 months: 24/24 Follow up 6 months: 24/24 Follow up 12 months: 24/24 Follow up 24 months: 23/24
<b>Outcomes</b>	SF-36 Subscales: 8 subscales, VAS – intensity,
<b>Comments</b>	

**Vas 2016**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Vas 2016 Spain [43]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Three primary care centers Referred by general practitioner.
<b>Population</b> <b>Inclusion criteria</b>	Adults (17 years of age or more) w a diagnosis in Fibromyalgia according to ACR criteria.
<b>Follow up</b>	End of treatment (10 weeks), 6 months and 12 months.
<b>Intervention 1</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Acupuncture Individualised treatment based on diagnostics using Traditional Chinese Medicine. 82 Follow up 10 weeks:78/82 Follow up 6 months: 75/82 Follow up 12 months: 73/82
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Sham intervention Simulated acupuncture on dorsal and lumbar regions. 82 Follow up 10 weeks:81/82 Follow up 6 months: 80/82 Follow up 12 months: 80/82
<b>Outcomes</b>	FIQ - total score, SF-36 (SF-12) Subscales: 1) Mental components, 2) Physical components, VAS – intensity, Hamilton Rating Scale for depression (HAM-D)
<b>Comments</b>	

## Behandlingar som undersökts i enbart en studie

### Studier inom behandling med läkemedel

#### Arnold 2007

Author	Arnold
Year	2007
Country	USA
Ref #	[44]
Study design	Randomized controlled trial
Setting	3 outpatient research centres
Recruitment	Patients were identified by physician referral or response to an advertisement for a fibromyalgia medication trial.
Population	Female or male patients, 18 year or older and met ACR90 diagnostic criteria Patients were required to score $\geq 4$ on the average pain severity item of the Brief Pain Inventory (BPI) at screening and randomization.
Inclusion criteria	Exclusion criteria (selected): Patients with other rheumatic or medical disorders that contributed to the symptoms of fibromyalgia were excluded. Patients patients who, in the opinion of the investigator, were treatment refractory, patients prior treatment with gabapentin or pregabalin
Follow up	Post treatment (12 weeks of treatment phase).
Intervention 1	Gabapentin titrated up to 2,400 mg/day during first 6 weeks of treatment phase. The dose was reduced to 1,200 mg/day for patients who could not tolerate target dose.
Participants (n)	75
Drop-outs (n)	18/75
Comparison	Placebo
Participants (n)	75
Drop-outs (n)	13/72
Outcomes	BPI, pain severity and pain interference scores FIQ total score (range 0–80) Clinical Global Impression of Severity (range 1–7) MOS sleep measure MADRAS SF-36 (8 subscales) Adverse events
Comments	Study medication dose was stable for the last 4 weeks of the therapy phase.

#### Miki 2016

Author	Miki
Year	2016
Country	Japan
Ref #	[45]
Study design	Randomized controlled trial
Setting	Tertiary care hospitals
Recruitment	Not stated
Population	Male or female patients aged between 20 and 64 years who met the ACR90 diagnostic criteria for FM
Inclusion criteria	
Follow up	Post treatment (12 weeks).
Intervention 1	Mirtazapine
Participants (n)	215



<b>Drop-outs (n)</b>	Analyzed: 211/215 Lost to follow up: 3/215 Discontinued intervention: 23/215
<b>Comparison Participants (n) Drop-outs (n)</b>	Placebo 215 Analyzed: 211/215 Lost to follow up: 2/215 Discontinued intervention: 23/215
<b>Outcomes</b>	SF-36 Subscales: 1) Mental components 2) Physical components 3) Role/ social components 4) 8 subscales NRS - Intensity
<b>Comments</b>	

**Ramzy 2017**

<b>Author Year Country Ref #</b>	Ramzy 2017 Egypt [46]
<b>Study design Setting Recruitment</b>	Randomized controlled trial Not stated Not stated
<b>Population</b>	Subjects included 75 adult women (> 18 and < 70 years of age) who were previously diagnosed with fibromyalgia according to the standard 2010 criteria of the ACR3 (Appendix 1) and who were available for the entire 6 months of the study protocol.
<b>Inclusion criteria</b>	
<b>Follow up</b>	bimonthly for 6 consecutive months
<b>Intervention 1 Participants (n) Drop-outs (n)</b>	Amitriptyline Pregabalin 75 mg/dag och Amitriptylin 25 mg/dag 24 End of study: 24/24
<b>Intervention 2 Participants (n) Drop-outs (n)</b>	Venlafaxine Pregabalin 75 mg/dag och Venlafaxin 75 mg/dag 25 End of study: 25/25
<b>Intervention 3 Participants (n) Drop-outs (n)</b>	Paroxetine Pregabalin 75 mg/dag och Paroxetin 25 mg/dag 26 End of study: 26/26
<b>Outcomes</b>	Somatic Symptoms Scale-8 (SSS-8) Subscale: severity, CES-D
<b>Comments</b>	

## Studier inom psykologisk behandling

### Broderick 2005

<b>Author</b>	Broderick
<b>Year</b>	2005
<b>Country</b>	
<b>Ref #</b>	[47]
<b>Study design</b>	Randomized controlled trial.
<b>Setting</b>	
<b>Recruitment</b>	Notices in local newspapers and an academic hospital and by contacting patients in laboratory database.
<b>Population</b>	Women older than 21 years of age with a Fibromyalgia diagnosis by a physician.
<b>Inclusion criteria</b>	
<b>Follow up</b>	End of treatment (3 weeks), follow up at 4 months and 10 months.
<b>Intervention 1</b>	Emotional Disclosure Three 20-minute writing sessions in the laboratory with approximately 1-week intervals. Retelling of an important current or past traumatic event with emotional expression and cognitive reappraisal.
<b>Participants (n)</b>	31
<b>Drop-outs (n)</b>	Post treatment: 29/31 4 months follow up: 28/31 10 months follow up: 26/31
<b>Intervention 2</b>	Neutral writing Three 20-minute writing sessions in the laboratory with approximately 1-week intervals. Write about day-to-day activities in relation to the time invested.
<b>Participants (n)</b>	32
<b>Drop-outs (n)</b>	Post treatment: 26/32 4 months follow up: 26/32 10 months follow up: 26/32
<b>Comparison</b>	Treatment as usual
<b>Participants (n)</b>	29
<b>Drop-outs (n)</b>	Post treatment: 29/29 4 months follow up: 29/29 10 months follow up: 28/29
<b>Outcomes</b>	FIQ Subscale: Physical function, The Quality of Life Scale (QoL) Total score, Brief Pain Inventory (BPI) Subscale: Interference, McGill Pain questionnaire (MPQ) Total score and subscales, Beck Depression Inventory-II (BDI-II), Anxiety Trait and State (STAI), MOS - Sleep Scale Subscales: 1) Energy 2) Fatigue.
<b>Comments</b>	

### Martinez 2014

<b>Author</b>	Martinez
<b>Year</b>	2014
<b>Country</b>	Spain
<b>Ref #</b>	[48]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	At a university hospital rheumatology unit
<b>Recruitment</b>	Patients were recruited from the Rheumatology Service and Pain Unit
<b>Population</b>	Women aged 25 – 60, diagnosed with FM (ACR 1990) since more than 6 months.

<b>Inclusion criteria</b>	Being stable as regards the intake of analgesics, antidepressants or other drugs at least 1 month before the study, and meeting the diagnostic criteria for insomnia.
<b>Follow up</b>	Post treatment, at 3 and 6 months after intervention.
<b>Intervention 1</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	CBT - insomnia 32 Completed treatment: 30/32 Follow up post treatment: 30/32 Follow up at 3 months: 29/32 Follow up at 6 months: 27/32
<b>Intervention 2</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Sleep hygiene 32 Completed treatment: 29/32 Follow up post treatment: 27/32 Follow up at 3 months: 22/32 Follow up at 6 months: 20/32
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Not included
<b>Outcomes</b>	FIQ - total score, SF-36 Mental component summary, McGill Pain questionnaire (MPQ), MPQ-SF (short form), The Symptom Checklist-90 (SCL-90) Subscales: 1) Depression 2) Anxiety, Pittsburgh Sleep Quality Index (PSQI) Total score and subscales, Multidimensional Pain Inventory (MPI) Subscale: fatigue, Pain catastrophizing scale (PCS) Total score, Chronic Pain Self-efficacy Scale (CPSS) Total score
<b>Comments</b>	

**Scheidt 2013**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Scheidt 2013 Germany [49]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial University medical center. Via patient self-help groups, news media and referrals from the Department of Rheumatology.
<b>Population</b>	Women, 18–70 years of age, who currently suffered from fibromyalgia as (ACR).
<b>Inclusion criteria</b>	Only participants suffering from current depression or anxiety disorder [International Classification of Diseases, 10th Revision (ICD-10) diagnosis of a major depressive episode, recurrent depression, dysthymia, depressive adjustment disorder or anxiety disorder] were included. Additional inclusion criteria were command of the German language and informed consent
<b>Follow up</b>	Post treatment (25 weeks) and 12 months postintervention.
<b>Intervention 1</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Adapted form of short-term psychodynamic psychotherapy 25 weekly 1-hour sessions of psychodynamic psychotherapy 24 Received intervention: 23/24 Post treatment: 20/24 4 months follow up: 18/24 Intention to treat: 23
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Treatment as usual Four 10-15-minute contacts during a 6-months period. 23 Post treatment: 20/23 4 months follow up: 17/23 Intention to treat: 23

<b>Outcomes</b>	FIQ Total score, SF-36 Subscales: 1) Physical function 2) Mental health, Hospital Anxiety and Depression Score (HADS) Subscales: 1) Depression 2) Anxiety, The Symptom Checklist-90 (SCL-90) SCL-27 (short form), Pain Disability Index (PDI) Total score,
<b>Comments</b>	

## Studier inom psykoedukativa interventioner

### Hammond 2006

<b>Author</b>	Hammond
<b>Year</b>	2006
<b>Country</b>	United Kingdom
<b>Ref #</b>	[50]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Community leisure centres.
<b>Recruitment</b>	From a rheumatology outpatient department at one district general hospital.
<b>Population</b>	Adults (>18 years) with fibromyalgia according to ACR 1990 criteria.
<b>Inclusion criteria</b>	
<b>Follow up</b>	4 and 8 months.
<b>Intervention 1</b>	Patient Education Weekly education classes in groups over 10 weeks. Comprehensive education program based on social cognitive theory and self-management CBT approach. Education about medical and psychological aspects of fibromyalgia and physical exercises given in 2-hour sessions.
<b>Participants (n)</b>	71
<b>Drop-outs (n)</b>	Received intervention: 71/71 Assessment at 4 months: 53/71 Assessment at 8 months: 52/71
<b>Comparison</b>	Relaxation Booklet on fibromyalgia and 1 hour classes in relaxation. Classes once a week for 10 weeks.
<b>Participants (n)</b>	62
<b>Drop-outs (n)</b>	Received intervention: 62/62 Assessment at 4 months: 51/62 Assessment at 8 months: 49/62
<b>Outcomes</b>	FIQ - total score and FIQ - 8 sub scales, SF-36, MOS Sleep Scale (SP-12), Arthritis Self-Efficacy Scale (ASES)
<b>Comments</b>	

### Hsu 2010

<b>Author</b>	Hsu
<b>Year</b>	2010
<b>Country</b>	USA
<b>Ref #</b>	[51]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	
<b>Recruitment</b>	Patients recruited through fliers, advertisements and presentations at fibromyalgia support groups
<b>Population</b>	Adult (18 years or more) women w fibromyalgia (according ACR 1990 criteria)
<b>Inclusion criteria</b>	

<b>Follow up</b>	At end of treatment (6 weeks post randomization) and 6 months.
<b>Intervention 1</b>	Affective self awareness Three weekly 2-hour manual-based group sessions conducted by a physician. Four components: education on a psychophysiological model of pain, written emotional disclosure on stress, affective awareness techniques and re-engagement in activities.
<b>Participants (n)</b> <b>Drop-outs (n)</b>	24 Completed 6 week follow up: 21/24 Completed 6 month follow up: 21/24
<b>Comparison</b> <b>Participants (n)</b> <b>Drop-outs (n)</b>	Wait list 21 Completed 6 week follow up: 21/21 Completed 6 month follow up: 21/21
<b>Outcomes</b>	SF-36, Brief Pain Inventory (BPI), MOS Sleep Scale, Multidimensional Fatigue Inventory (MFI), Beliefs about Pain Control Questionnaire (BPCQ)
<b>Comments</b>	

**Stuifberger 2010**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Stuifberger 2010 United States [52]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial Primary care setting. Notices in local newspapers and websites, fliers in physician offices, community sites and support groups.
<b>Population</b>  <b>Inclusion criteria</b>	Female 20–75 years of age, having physician-diagnosed fibromyalgia syndrome for at least six months, and willing to participate.
<b>Follow up</b>	At 2, 5 and 8 months after baseline.
<b>Intervention 1</b>	Intervention group Designed to engage women with fibromyalgia syndrome in assessing their present health behaviours, setting meaningful goals for change and addressing the barriers, resources and skills necessary to change those behaviours.
<b>Participants (n)</b> <b>Drop-outs (n)</b>	123 Received intervention: 98/123 (Analysed with RM ANOVA) Follow up at 2 months: 88/123 Follow up at 5 months: 87/123 Follow up at 8 months: 84/123
<b>Comparison</b>  <b>Participants (n)</b> <b>Drop-outs (n)</b>	Treatment as usual Participants randomly assigned to the attention-control group received eight classroom sessions on topics related to disease management that were carefully scripted so that content did not overlap with that presented in the intervention classes. 111 Received intervention: 89/111 (Analysed with RM ANOVA) Follow up at 2 months: 83/111 Follow up at 5 months: 83/111 Follow up at 8 months: 81/111
<b>Outcomes</b>	FIQ - total score, SF-36: 1) Mental components 2) Physical components The Health Promoting Lifestyle Profile II (HPLP-II) Total score plus 6 subscales.
<b>Comments</b>	

## Studier inom fysisk aktivitet och manuella behandlingar

### Ang 2013

<b>Author</b>	Ang
<b>Year</b>	2013
<b>Country</b>	USA
<b>Ref #</b>	[53]
<b>Study design</b>	Randomized controlled trial.
<b>Setting</b>	Telephone-delivered intervention
<b>Recruitment</b>	Referred from specialty or primary care clinics.
<b>Population</b>	Between 18 and 65 years old, American College of Rheumatology classification criteria for FM.
<b>Inclusion criteria</b>	Average Brief Pain Inventory (BPI) pain severity score $\geq 4$ ; FIQ-PI score $\geq 2$ ; and on stable doses of medications for FM for more than 4 weeks.
<b>Follow up</b>	Post Treatment, at 3 and 6 months post treatment.
<b>Intervention 1</b>	Exercise based motivational interviewing Participants received 6 telephone calls over a 12-week period
<b>Participants (n)</b>	107
<b>Drop-outs (n)</b>	Post intervention, week 12: 97/107 3 months follow up: 95/107 6 months follow up: 97/107
<b>Comparison</b>	Education control Participants received 6 telephone calls over a 12-week period
<b>Participants (n)</b>	109
<b>Drop-outs (n)</b>	Post intervention, week 12: 102/109 3 months follow up: 98/109 6 months follow up: 101/109
<b>Outcomes</b>	FIQ Subscale: 1) Physical impairment, PHQ-8. Depression,
<b>Comments</b>	

### Castro-Sánchez 2011a

<b>Author</b>	Castro-Sánchez
<b>Year</b>	2011
<b>Country</b>	Spain
<b>Ref #</b>	[54]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	
<b>Recruitment</b>	Patients diagnosed with FMS (ACR) who belong to a Fibromyalgia Association.
<b>Population</b>	FMS diagnosis, age from 18 to 65 years (working age range), no regular physical activity, and agreement to attend evening therapy sessions.
<b>Inclusion criteria</b>	Agreement to attend evening therapy sessions, limitation of usual activities due to pain on at least 1 day in the previous 30 days, and/or moderate or worse average pain level ( $\leq 4$ on 10-point scale).
<b>Follow up</b>	End of treatment (20 weeks), 1 months and 6 months.
<b>Intervention 1</b>	Massage Myofascial release therapy Massage-myofascial release therapy during a weekly 90-minute session for 20 weeks. Aimed to release myofascial restrictions at the sites of the 18 painful points.
<b>Participants (n)</b>	32
<b>Drop-outs (n)</b>	Analyzed: 30/32
<b>Comparison</b>	Sham

<b>Participants (n)</b> <b>Drop-outs (n)</b>	Weekly 30-minute session of disconnected magnetotherapy for 20 weeks. With the patient in prone position, magnotherapy was applied on the cervical area (15 min) and lumbar area (15 min). 32 Analyzed: 29/32
<b>Outcomes</b>	SF-36 Subscales: 8 subscales, Pittsburgh Sleep Quality Index (PSQI) Subscales: 1) Sleep quality, , 2) Sleep latency, 3) Sleep duration, 4) Sleep efficiency, 5) Sleep disturbance, 6) Daily dysfunction
<b>Comments</b>	

**Castro-Sánchez 2011b**

<b>Author</b> <b>Year</b> <b>Country</b> <b>Ref #</b>	Castro-Sánchez 2011 Spain [55]
<b>Study design</b> <b>Setting</b> <b>Recruitment</b>	Randomized controlled trial
<b>Population</b>	Age 40–65 years, patients diagnosed with fibromyalgia syndrome by physicians.
<b>Inclusion criteria</b>	Agreement to attend evening therapy sessions, limitation of usual activities due to pain on at least 1 day in the previous 30 days, and/or moderate or worse average pain level ( $\leq 4$ on 10-point scale).
<b>Follow up</b>	End of treatment (20 weeks), 6 months and 12 months.
<b>Intervention 1</b>	Myofascial release therapy Twice-weekly for 20 weeks, 1-hour session of 10 myofascial release modalities.
<b>Participants (n)</b> <b>Drop-outs (n)</b>	47 Analyzed: 45/47
<b>Comparison</b>	Sham Short-wave and ultrasound treatment for 30 minutes twice-weekly for 20 weeks.
<b>Participants (n)</b> <b>Drop-outs (n)</b>	47 Analyzed: 41/47
<b>Outcomes</b>	FIQ - total score and 5 subscales: 1) N Days feeling good, 2) Pain, 3) Fatigue, 4) Tiredness walking, 5) Stiffness, VAS – intensity, McGill Pain Questionnaire (MPG) Subscales: 1) Sensory, 2) Affective, 3) Sensory and affective subscales combined, Clinician Global Impression (CGI) 1) Severity, 2) Improvement
<b>Comments</b>	

## Annan behandling

### Mhalla 2011

<b>Author</b>	Mhalla
<b>Year</b>	2011
<b>Country</b>	Not stated.
<b>Ref #</b>	[56]
<b>Study design</b>	Randomized controlled trial
<b>Setting</b>	Not stated.
<b>Recruitment</b>	Not stated.
<b>Population</b>	Female patients of at least 18 years of age, who fulfilled ACR-90 criteria, pain intensity $\geq 4$ (BPI).
<b>Inclusion criteria</b>	Patients with inflammatory rheumatic disease, autoimmune disease, or painful disorders that might confound assessment of FM pain or current primary psychiatric condition or substance abuse were not included. Patients with contraindication for TMS such as seizures, brain trauma, brain surgery och intracranial hypertension, neurological disorders, pacemaker or other metallic implants were excluded. Stable medication for pain and sleep disorders for at least one month before enrolment and throughout the study.
<b>Follow up</b>	Throughout treatment, at end of treatment and 4 weeks after end of treatment.
<b>Intervention 1</b>	Repetitive transcranial magnetic stimulation (rTMS). A total of 14 sessions over 21 weeks, consisting of an "induction phase" with one session per day for 5 days was followed by a "maintenance phase" consisting of one weekly session for 3 weeks, and 3 monthly sessions thereafter.
<b>Participants (n)</b>	20
<b>Drop-outs (n)</b>	3/20
<b>Comparison</b>	Sham
<b>Participants (n)</b>	20
<b>Drop-outs (n)</b>	5/20
<b>Outcomes</b>	Pain intensity SF-McGill questionnaire (sensory and affective dimensions of pain) Brief Pain Inventory (BPI) – interference Fibromyalgia Impact Questionnaire (FIQ) total score Hospital Anxiety and Depression Scale (HAD), anxiety and depression Beck Depression Inventory (BDI) Pain Catastrophizing Scale (PCS) Negative effects
<b>Comments</b>	



## Referenser

1. Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *J Rheumatol*. 2010;37(12):2578-86. Available from: <https://doi.org/10.3899/jrheum.100365>.
2. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. *Clin J Pain*. 2012;28(9):775-81. Available from: <https://doi.org/10.1097/AJP.0b013e3182510295>.
3. Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. *Arthritis Res Ther*. 2015;17(1):224. Available from: <https://doi.org/10.1186/s13075-015-0718-y>.
4. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Jr., Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. *J Pain*. 2008;9(9):792-805. Available from: <https://doi.org/10.1016/j.jpain.2008.03.013>.
5. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. *Arthritis Res Ther*. 2012;14(5):R217. Available from: <https://doi.org/10.1186/ar4056>.
6. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. *J Rheumatol*. 2011;38(12):2643-52. Available from: <https://doi.org/10.3899/jrheum.110569>.
7. Alda M, Luciano JV, Andrés E, Serrano-Blanco A, Rodero B, del Hoyo YL, et al. Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: a randomised controlled trial. *Arthritis Res Ther*. 2011;13(5):R173. Available from: <https://doi.org/10.1186/ar3496>.
8. Castel A, Cascón R, Padrol A, Sala J, Rull M. Multicomponent cognitive-behavioral group therapy with hypnosis for the treatment of fibromyalgia: long-term outcome. *J Pain*. 2012;13(3):255-65. Available from: <https://doi.org/10.1016/j.jpain.2011.11.005>.
9. Falcao D, Sales L, Leite J, Feldman D, Valim V, Natour J. Cognitive behavioral therapy for the treatment of fibromyalgia syndrome: a randomized controlled trial. *Journal of Musculoskeletal Pain*. 2008;16(3):133-40.
10. Karlsson B, Burell G, Anderberg UM, Svärdsudd K. Cognitive behaviour therapy in women with fibromyalgia: A randomized clinical trial. *Scand J Pain*. 2015;9(1):11-21. Available from: <https://doi.org/10.1016/j.sjpain.2015.04.027>.
11. McCrae CS, Williams J, Roditi D, Anderson R, Mundt JM, Miller MB, et al. Cognitive behavioral treatments for insomnia and pain in adults with comorbid chronic insomnia and fibromyalgia: clinical outcomes from the SPIN randomized controlled trial. *Sleep*. 2019;42(3). Available from: <https://doi.org/10.1093/sleep/zsy234>.

12. Vallejo MA, Ortega J, Rivera J, Comeche MI, Vallejo-Slocker L. Internet versus face-to-face group cognitive-behavioral therapy for fibromyalgia: A randomized control trial. *J Psychiatr Res*. 2015;68:106-13. Available from: <https://doi.org/10.1016/j.jpsychires.2015.06.006>.
13. Woolfolk RL, Allen LA, Apter JT. Affective-cognitive behavioral therapy for fibromyalgia: a randomized controlled trial. *Pain Res Treat*. 2012;2012:937873. Available from: <https://doi.org/10.1155/2012/937873>.
14. Lumley MA, Schubiner H, Lockhart NA, Kidwell KM, Harte SE, Clauw DJ, et al. Emotional awareness and expression therapy, cognitive behavioral therapy, and education for fibromyalgia: a cluster-randomized controlled trial. *Pain*. 2017;158(12):2354-63. Available from: <https://doi.org/10.1097/j.pain.0000000000001036>.
15. Luciano JV, Guallar JA, Aguado J, López-Del-Hoyo Y, Olivan B, Magallón R, et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). *Pain*. 2014;155(4):693-702. Available from: <https://doi.org/10.1016/j.pain.2013.12.029>.
16. Simister HD, Tkachuk GA, Shay BL, Vincent N, Pear JJ, Skrabek RQ. Randomized Controlled Trial of Online Acceptance and Commitment Therapy for Fibromyalgia. *J Pain*. 2018;19(7):741-53. Available from: <https://doi.org/10.1016/j.jpain.2018.02.004>.
17. Cejudo J, García-Castillo FJ, Luna P, Rodrigo-Ruiz D, Feltrero R, Moreno-Gómez A. Using a Mindfulness-Based Intervention to Promote Subjective Well-Being, Trait Emotional Intelligence, Mental Health, and Resilience in Women With Fibromyalgia. *Front Psychol*. 2019;10:2541. Available from: <https://doi.org/10.3389/fpsyg.2019.02541>.
18. Schmidt S, Grossman P, Schwarzer B, Jena S, Naumann J, Walach H. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. *Pain*. 2011;152(2):361-9. Available from: <https://doi.org/10.1016/j.pain.2010.10.043>.
19. Sephton SE, Salmon P, Weissbecker I, Ulmer C, Floyd A, Hoover K, et al. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: results of a randomized clinical trial. *Arthritis and rheumatism*. 2007;57(1):77-85. Available from: <https://doi.org/10.1002/art.22478>.
20. Pérez-Aranda A, Feliu-Soler A, Montero-Marín J, García-Campayo J, Andrés-Rodríguez L, Borràs X, et al. A randomized controlled efficacy trial of mindfulness-based stress reduction compared with an active control group and usual care for fibromyalgia: the EUDAIMON study. *Pain*. 2019;160(11):2508-23. Available from: <https://doi.org/10.1097/j.pain.0000000000001655>.
21. Van Gordon W, Shonin E, Dunn TJ, Garcia-Campayo J, Griffiths MD. Meditation awareness training for the treatment of fibromyalgia syndrome: A randomized controlled trial. *Br J Health Psychol*. 2017;22(1):186-206. Available from: <https://doi.org/10.1111/bjhp.12224>.
22. Barrenengoa-Cuadra MJ, Muñoa-Capron-Manieux M, Fernández-Luco M, Angón-Puras L, Romón-Gómez AJ, Azkuenaga M, et al. Effectiveness of a structured group intervention based on pain neuroscience education for patients with fibromyalgia in primary care: A multicentre randomized open-label controlled trial. *Eur J Pain*. 2021;25(5):1137-49. Available from: <https://doi.org/10.1002/ejp.1738>.

23. Luciano JV, Martínez N, Peñarrubia-María MT, Fernández-Vergel R, García-Campayo J, Verduras C, et al. Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. *Clin J Pain*. 2011;27(5):383-91. Available from: <https://doi.org/10.1097/AJP.0b013e31820b131c>.
24. Luciano JV, Sabes-Figuera R, Cardeñosa E, M TP-M, Fernández-Vergel R, García-Campayo J, et al. Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial. *Clin J Pain*. 2013;29(8):702-11. Available from: <https://doi.org/10.1097/AJP.0b013e318270f99a>.
25. Musekamp G, Gerlich C, Ehlebracht-Ki Nig I, Dorn M, A HF, Tomiak C, et al. Evaluation of a self-management patient education programme for fibromyalgia-results of a cluster-RCT in inpatient rehabilitation. *Health Educ Res*. 2019;34(2):209-22. Available from: <https://doi.org/10.1093/her/cyy055>.
26. Baptista AS, Villela AL, Jones A, Natour J. Effectiveness of dance in patients with fibromyalgia: a randomized, single-blind, controlled study. *Clin Exp Rheumatol*. 2012;30(6 Suppl 74):18-23.
27. Carson JW, Carson KM, Jones KD, Bennett RM, Wright CL, Mist SD. A pilot randomized controlled trial of the Yoga of Awareness program in the management of fibromyalgia. *Pain*. 2010;151(2):530-9. Available from: <https://doi.org/10.1016/j.pain.2010.08.020>.
28. Carson JW, Carson KM, Jones KD, Mist SD, Bennett RM. Follow-up of yoga of awareness for fibromyalgia: results at 3 months and replication in the wait-list group. *Clin J Pain*. 2012;28(9):804-13. Available from: <https://doi.org/10.1097/AJP.0b013e31824549b5>.
29. Da Costa D, Abrahamowicz M, Lowensteyn I, Bernatsky S, Dritsa M, Fitzcharles MA, et al. A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. *Rheumatology (Oxford)*. 2005;44(11):1422-7. Available from: <https://doi.org/10.1093/rheumatology/kei032>.
30. Fontaine KR, Conn L, Clauw DJ. Effects of lifestyle physical activity on perceived symptoms and physical function in adults with fibromyalgia: results of a randomized trial. *Arthritis Res Ther*. 2010;12(2):R55. Available from: <https://doi.org/10.1186/ar2967>.
31. Fontaine KR, Conn L, Clauw DJ. Effects of lifestyle physical activity in adults with fibromyalgia: results at follow-up. *J Clin Rheumatol*. 2011;17(2):64-8. Available from: <https://doi.org/10.1097/RHU.0b013e31820e7ea7>.
32. Haak T, Scott B. The effect of Qigong on fibromyalgia (FMS): a controlled randomized study. *Disabil Rehabil*. 2008;30(8):625-33. Available from: <https://doi.org/10.1080/09638280701400540>.
33. Mannerkorpi K, Nordeman L, Cider A, Jonsson G. Does moderate-to-high intensity Nordic walking improve functional capacity and pain in fibromyalgia? A prospective randomized controlled trial. *Arthritis Res Ther*. 2010;12(5):R189. Available from: <https://doi.org/10.1186/ar3159>.
34. Paolucci T, Baldari C, Di Franco M, Didona D, Reis V, Vetrano M, et al. A New Rehabilitation Tool in Fibromyalgia: The Effects of Perceptive Rehabilitation on Pain and Function in a Clinical Randomized Controlled Trial. *Evid Based Complement Alternat Med*. 2016;2016:7574589. Available from: <https://doi.org/10.1155/2016/7574589>.

35. Altan L, Korkmaz N, Bingol U, Gunay B. Effect of pilates training on people with fibromyalgia syndrome: a pilot study. *Arch Phys Med Rehabil.* 2009;90(12):1983-8. Available from: <https://doi.org/10.1016/j.apmr.2009.06.021>.
36. Calandre EP, Rodriguez-Claro ML, Rico-Villademoros F, Vilchez JS, Hidalgo J, Delgado-Rodriguez A. Effects of pool-based exercise in fibromyalgia symptomatology and sleep quality: a prospective randomised comparison between stretching and Ai Chi. *Clin Exp Rheumatol.* 2009;27(5 Suppl 56):S21-8.
37. Kayo AH, Peccin MS, Sanches CM, Trevisani VF. Effectiveness of physical activity in reducing pain in patients with fibromyalgia: a blinded randomized clinical trial. *Rheumatol Int.* 2012;32(8):2285-92. Available from: <https://doi.org/10.1007/s00296-011-1958-z>.
38. Richards SC, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. *Bmj.* 2002;325(7357):185. Available from: <https://doi.org/10.1136/bmj.325.7357.185>.
39. Wang C, Schmid CH, Roncs R, Kalish R, Yin H, Goldenberg DL, et al. A randomized trial of tai chi for fibromyalgia. *N Engl J Med.* 2010;363(8):743-54. Available from: <https://doi.org/10.1056/NEJMoa0912611>.
40. Wang C, Schmid CH, Fielding RA, Harvey WF, Reid KF, Price LL, et al. Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. *Bmj.* 2018;360:k851. Available from: <https://doi.org/10.1136/bmj.k851>.
41. Assefi NP, Sherman KJ, Jacobsen C, Goldberg J, Smith WR, Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. *Ann Intern Med.* 2005;143(1):10-9. Available from: <https://doi.org/10.7326/0003-4819-143-1-200507050-00005>.
42. Targino RA, Imamura M, Kaziyama HH, Souza LP, Hsing WT, Furlan AD, et al. A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. *J Rehabil Med.* 2008;40(7):582-8. Available from: <https://doi.org/10.2340/16501977-0216>.
43. Vas J, Santos-Rey K, Navarro-Pablo R, Modesto M, Aguilar I, Campos M, et al. Acupuncture for fibromyalgia in primary care: a randomised controlled trial. *Acupunct Med.* 2016;34(4):257-66. Available from: <https://doi.org/10.1136/acupmed-2015-010950>.
44. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, Jr., et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. *Arthritis and rheumatism.* 2007;56(4):1336-44. Available from: <https://doi.org/10.1002/art.22457>.
45. Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K. Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. *Pain.* 2016;157(9):2089-96. Available from: <https://doi.org/10.1097/j.pain.0000000000000622>.
46. Ramzy EA. Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study. *Pain Pract.* 2017;17(1):32-40. Available from: <https://doi.org/10.1111/papr.12409>.

47. Broderick JE, Junghaenel DU, Schwartz JE. Written emotional expression produces health benefits in fibromyalgia patients. *Psychosom Med*. 2005;67(2):326-34. Available from: <https://doi.org/10.1097/01.psy.0000156933.04566.bd>.
48. Martínez MP, Miró E, Sánchez AI, Díaz-Piedra C, Cáliz R, Vlaeyen JW, et al. Cognitive-behavioral therapy for insomnia and sleep hygiene in fibromyalgia: a randomized controlled trial. *J Behav Med*. 2014;37(4):683-97. Available from: <https://doi.org/10.1007/s10865-013-9520-y>.
49. Scheidt CE, Waller E, Endorf K, Schmidt S, König R, Zeeck A, et al. Is brief psychodynamic psychotherapy in primary fibromyalgia syndrome with concurrent depression an effective treatment? A randomized controlled trial. *Gen Hosp Psychiatry*. 2013;35(2):160-7. Available from: <https://doi.org/10.1016/j.genhosppsy.2012.10.013>.
50. Hammond A, Freeman K. Community patient education and exercise for people with fibromyalgia: a parallel group randomized controlled trial. *Clin Rehabil*. 2006;20(10):835-46. Available from: <https://doi.org/10.1177/0269215506072173>.
51. Hsu MC, Schubiner H, Lumley MA, Stracks JS, Clauw DJ, Williams DA. Sustained pain reduction through affective self-awareness in fibromyalgia: a randomized controlled trial. *J Gen Intern Med*. 2010;25(10):1064-70. Available from: <https://doi.org/10.1007/s11606-010-1418-6>.
52. Stuifbergen AK, Blozis SA, Becker H, Phillips L, Timmerman G, Kullberg V, et al. A randomized controlled trial of a wellness intervention for women with fibromyalgia syndrome. *Clin Rehabil*. 2010;24(4):305-18. Available from: <https://doi.org/10.1177/0269215509343247>.
53. Ang DC, Kaleth AS, Bigatti S, Mazzuca SA, Jensen MP, Hilligoss J, et al. Research to encourage exercise for fibromyalgia (REEF): use of motivational interviewing, outcomes from a randomized-controlled trial. *Clin J Pain*. 2013;29(4):296-304. Available from: <https://doi.org/10.1097/AJP.0b013e318254ac76>.
54. Castro-Sánchez AM, Matarán-Peñarrocha GA, Granero-Molina J, Aguilera-Manrique G, Quesada-Rubio JM, Moreno-Lorenzo C. Benefits of massage-myofascial release therapy on pain, anxiety, quality of sleep, depression, and quality of life in patients with fibromyalgia. *Evid Based Complement Alternat Med*. 2011a;2011a:561753. Available from: <https://doi.org/10.1155/2011/561753>.
55. Castro-Sánchez AM, Matarán-Peñarrocha GA, Arroyo-Morales M, Saavedra-Hernández M, Fernández-Sola C, Moreno-Lorenzo C. Effects of myofascial release techniques on pain, physical function, and postural stability in patients with fibromyalgia: a randomized controlled trial. *Clin Rehabil*. 2011b;25(9):800-13. Available from: <https://doi.org/10.1177/0269215511399476>.
56. Mhalla A, Baudic S, de Andrade DC, Gautron M, Perrot S, Teixeira MJ, et al. Long-term maintenance of the analgesic effects of transcranial magnetic stimulation in fibromyalgia. *Pain*. 2011;152(7):1478-85. Available from: <https://doi.org/10.1016/j.pain.2011.01.034>.